Japan – LEQEMBI(R) (lecanemab) Subcutaneous Formulation as an Initiation Treatment for Early Alzheimer’s Disease Approved in China

Eisai Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) revealed today that the National Medical Products Administration (NMPA) of China has actually authorized the subcutaneous formula (subcutaneous autoinjector: SC-AI), the anti-amyloid beta (Aβ) protofibril antibody LEQEMBI ® (generic name: lecanemab) as an initiation treatment for moderate cognitive disability (MCI) due to Alzheimer’s illness (ADVERTISEMENT) or moderate advertisement dementia (jointly described as early advertisement). The application was accepted by the NMPA in January 2026 and was consequently given Priority Review classification. Release is prepared throughout Eisai’s FY 2026, ending March 31, 2027.

LEQEMBI SC-AI is a self-administered autoinjector solution. The accepted routine is 500 mg offered as soon as weekly as 2 successive 250 mg injections. With this approval, LEQEMBI treatment now uses a brand-new choice of once-weekly SC administration in your home, in addition to intravenous (IV) administration every 2 weeks in a health center setting. Clients might likewise change from IV to SC administration, or vice versa, throughout treatment.

LEQEMBI SC-AI might considerably minimize the time needed compared to IV infusions (approximate injection time of 15 seconds per injection). In addition, at-home administration might decrease the problem of center sees for clients and their care partners and allow treatment alternatives that much better fit their way of lives, supplying higher versatility for heading out and taking a trip. The enhanced benefit and versatility of treatment with LEQEMBI is anticipated to lower barriers to starting and continuing treatment with LEQEMBI. LEQEMBI SC-AI likewise has the prospective to lower health care resources associated with IV dosing, such as nurse tracking, as well as keeping infusion capability. These functions are anticipated to add to more improving the general advertisement treatment path. For ARIA (amyloid-related imaging irregularities) tracking, just like IV administration, brain magnetic resonance imaging (MRI) is carried out prior to starting treatment and at defined time points after treatment initiation.

Advertisement is an unrelenting illness with Aβ and tau as trademarks, triggered by a constant underlying neurotoxic procedure driven by protofibrils that starts before amyloid plaque build-up and continues after plaque elimination.1,2,3 Only LEQEMBI battles advertisement in 2 methods– targeting both protofibrils and amyloid plaque.

This marks the 2nd nation internationally to authorize LEQEMBI SC-AI. This approval is based upon the incorporated outcomes of information and associated modeling and simulation from the 18-month core research study of the Phase 3 Clarity advertisement research study of LEQEMBI in clients with early advertisement, in addition to several subcutaneous (SC) administration sub-studies (consisting of the Chinese friend) in its subsequent long-lasting extension (LTE). Once-weekly administration of SC-AI 500mg showed direct exposure comparable to when every 2 weeks IV administration, with comparable medical and biomarker advantages. The total security profile of SC administration was usually comparable to that of IV administration. Injection-related responses were observed with subcutaneous LEQEMBI, the majority of which were localized, while systemic responses were less often observed.

Eisai approximates that there were 17 million clients with MCI or moderate dementia due to advertisement in China in 2024, which is anticipated to increase as the population ages. LEQEMBI was released in China in June 2024 and is leading the facility of anti-amyloid treatment in advertisement management, broadening its contribution to clients with early advertisement.

Eisai works as the lead of LEQEMBI advancement and regulative submissions internationally with Eisai and Biogen co-commercializing and co-promoting the item and Eisai having last decision-making authority. Eisai will disperse the item in China and will perform details arrangement activities through specialized medical agents.

About lecanemab (generic name, brand: LEQEMBI ®)

Lecanemab is the outcome of a tactical research study alliance in between Eisai and BioArctic. It is a humanized immunoglobulin gamma (IgG1) monoclonal antibody directed versus aggregated soluble (protofibril) and insoluble types of amyloid-beta (Aβ).

Lecanemab has actually been authorized in 53 nations and areas consisting of Japan, the U.S., China, Canada, Europe, South Korea, Taiwan, and Saudi Arabia, and is under regulative evaluation in 6 nations. Following the preliminary stage with treatment every 2 weeks for 18 months, intravenous (IV) upkeep dosing with treatment every 4 weeks is authorized in 9 nations and areas consisting of the U.S., China, the UK, and others, and applications have actually been submitted in 11 nations and areas. The U.S. FDA authorized Eisai’s Biologics License Application (BLA) for subcutaneous upkeep dosing with LEQEMBI IQLIK in August 2025. For subcutaneous initiation treatment (500 mg), approval was gotten in the United States in July 2026, and applications are under evaluation in 3 nations, consisting of Japan.

LEQEMBI’s approvals in these nations were based upon Phase 3 information from Eisai’s international placebo-controlled, double-blind, parallel-group, randomized Clarity advertisement scientific trial, in which it satisfied its main endpoint and all crucial secondary endpoints with statistically considerable outcomes. The main endpoint was the international cognitive and practical scale, Clinical Dementia Rating Sum of Boxes (CDR-SB). Clearness advertisement assessed lecanemab 10 mg/kg bi-weekly IV treatment of early Alzheimer’s illness, which included 1,795 clients (treatment group: 898, placebo group: 897). 95% of clients who finished the core research study (18 months) selected to continue in the long-lasting extension research study (LTE), with 478 clients still getting treatment for 4 years. In the Clarity advertisement core scientific research study, information revealed LEQEMBI IV substantially slowed illness development at 18 months (27% vs placebo), and the mean modification from standard in between the lecanemab dealt with group and the placebo group after 18 months was -0.45 (P=0.00005) on the main endpoint of CDR-SB worldwide cognitive and practical scale.

Because July 2020, the Phase 3 scientific research study (AHEAD 3-45) for people with preclinical advertisement, suggesting they are medically regular and have intermediate or raised levels of amyloid in their brains, is continuous. AHEAD 3-45 is carried out as a public-private collaboration in between the Alzheimer’s Clinical Trial Consortium that supplies the facilities for scholastic scientific trials in advertisement and associated dementias in the U.S, moneyed by the National Institute on Aging, part of the National Institutes of Health, Eisai and Biogen. Given that January 2022, the Tau NexGen medical research study for Dominantly Inherited Advertisement (DIAD), that is carried out by Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), led by Washington University School of Medicine in St. Louis, is continuous and consists of lecanemab as the foundation anti-amyloid treatment.

About Protofibrils

Protofibrils are believed to be the most harmful Aβ types that add to mental retardation in advertisement and play a significant function in the cognitive decrease of this progressive and destructive illness. Protofibrils can trigger neuronal and synaptic damage in the brain, which can consequently negatively impact cognitive function through several systems.2 The system by which this happens has actually been reported not just by increasing the development of insoluble Aβ plaques, however likewise by straight harmful signaling in between nerve cells and other cells. It is thought that minimizing protofibrils might minimize neuronal damage and cognitive disability, possibly avoiding the development of advertisement.3

About the Collaboration in between Eisai and Biogen for advertisement

Eisai and Biogen have actually been working together on the joint advancement and commercialization of advertisement treatments considering that 2014. Eisai acts as the lead of lecanemab advancement and regulative submissions internationally with both business co-commercializing and co-promoting the item and Eisai having last decision-making authority.

About the Collaboration in between Eisai and BioArctic for advertisement

Given that 2005, Eisai and BioArctic have actually had a long-lasting cooperation relating to the advancement and commercialization of advertisement treatments. Eisai acquired the worldwide rights to study, establish, produce and market lecanemab for the treatment of advertisement pursuant to a contract with BioArctic in December 2007. The advancement and commercialization contract on the antibody lecanemab back-up was checked in May 2015.

About Eisai Co., Ltd.

Eisai’s Corporate Concept is “to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides.” Under this Concept (likewise called human healthcare (hhc) Concept), we intend to efficiently accomplish social great in the type of eliminating stress and anxiety over health and decreasing health variations. With a worldwide network of R&D centers, producing websites and marketing subsidiaries, we make every effort to develop and provide ingenious items to target illness with high unmet medical requirements, with a specific focus in our tactical locations of Neurology and Oncology.

In addition, we show our dedication to the removal of disregarded tropical illness (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by dealing with numerous activities together with international partners.

To learn more about Eisai, please see www.eisai.com (for international head office: Eisai Co., Ltd.), and get in touch with us on X, LinkedIn and Facebook. The site and social networks channels are meant for audiences beyond the UK and Europe. For audiences based in the UK and Europe, please see www.eisai.eu and Eisai EMEA LinkedIn.

About Biogen

Established in 1978, Biogen is a leading biotechnology business that leaders ingenious science to provide brand-new medications to change client’s lives and to produce worth for investors and our neighborhoods. We use deep understanding of human biology and take advantage of various techniques to advance first-in-class treatments or treatments that provide exceptional results. Our method is to take strong dangers, stabilized with roi to provide long-lasting development.

The business consistently posts details that might be essential to financiers on its site at www.biogen.com. Follow Biogen on social networks– Facebook, LinkedIn, X, YouTube.